Vaccines plays a significant role in prevention and control of different forms of infectious diseases. In the previous years, killed or attenuated vaccines were used, while gradually transitioning to recombinant subunit approach in the last two decades. Use of recombinant technologies in production of subunit vaccines makes a process more simplified, safe and cost effective. A recombinant vaccine is manufactured by using recombinant DNA technology and it offers prime advantage that there is complete absence of pathogens during the production and purification procedure, thus making the production procedure safer.  

The research study titled “Recombinant Vaccines Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” covers in-depth information related to recombinant vaccines market. The research study provides comprehensive analysis based on different market segments such as disease type and geography. Infectious diseases and cancer are covered in disease type segment analysis. Infectious diseases segment is further classified as hepatitis B infection, herpes zoster infection, influenza infection and other infectious diseases. 

North America (comprising United States and Canada), Europe (with United Kingdom and Germany), Asia Pacific (including Japan and China), Latin America (comprising Mexico and Brazil) and Middle East and Africa (GCC) cumulatively form the global recombinant vaccines market. Market size and forecast for these regions along with their cross-sectional segmentation are provided in this report for the considered period. The regional markets are further studied in terms of major country specific markets.

Quantitative data and qualitative information are included in this report for further understanding about the current market situation and future scenarios. Information such as market dynamics (drivers, opportunities and challenges) gives the detailed idea about the current developments in the global recombinant vaccines market. In order to help strategic decisions about the recombinant vaccines market, competitive profiling of the prominent players, attractive investment proposition, and market position of key leaders involved in the global recombinant vaccine market also included in report.  

Based on disease type, the global recombinant vaccines market is segmented as follows:  

• Infectious diseases
  • Hepatitis B Infection
  • Herpes Zoster Infection
  • Influenza Infection
  • Other Infectious Diseases
• Cancer

According to the World Health Organization (WHO), the vaccines market is essentially dependent on governments of industrialized and developing countries, private sectors, and the various regulatory and advisory bodies. Recombinant DNA vaccines are third generation vaccines, produced by using recombinant DNA technology or genetic engineering to prevent different diseases. These vaccines are more advanced as compare to conventional vaccines in preventing dieses such as hepatitis, herpes, papilloma virus infection, influenza etc. Recombinant vaccines market will grow significantly during forecast period as it involves a novel method to elicit humoral as well as cellular immune response, reduced risk of pathogenicity and easier approach for large scale production.

In 1986, the first hepatitis B recombinant vaccine was approved in the United State. Currently, hepatitis B infection is major revenue generating segment as hepatitis B vaccine is included in the World Health Organization's list of essential medicines. Moreover, the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP) and American College of Obstetricians and Gynecologists (ACOG) also strongly recommend hepatitis B vaccination.  Currently, hepatitis B recombinant vaccines revenue is largely generated by Engerix-B, Recombivax-HB, Pediarix, Comvax, Twinrix etc. GlaxoSmithKline and Merck are the key players in hepatitis B vaccines market. Promising pipeline vaccines such as VPM1002 (BCG), EBOV-GP (Ebola), Shingrix (Herpes Zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF (Prostate Cancer) etc. are expected to further assist the market growth during forecast period 2017-2025.

For the purpose of this study, the recombinant vaccines market is categorized into:

• North America
  • United States
  • Canada
• Europe
  • United Kingdom
  • Germany
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • Rest of Europe
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

Recombinant vaccine is a more advanced, efficient and safer technique, produced by using recombinant DNA technology or genetic engineering. According to the World Health Organization (WHO), demand for vaccines mainly depends on governments of country, pooling of procurement agencies, proliferation of private players, and presence and involvement of various regulatory and regulatory bodies overseeing vaccines safety and quality. The WHO also estimated that, high income countries such as the United States, United Kingdom, and France etc. contribute over 80% vaccines revenue due to faster adoption of newer vaccines and higher costs. It is studied that in 2016, North America held largest market share due to higher cost of recombinant vaccines, higher healthcare awareness, strong recommendation of immunization programs, faster implementation of newer vaccines and wide availability of FDA approved recombinant vaccines for different indications. Favorable R&D activities and strong presence of pipeline vaccines such as VPM1002, EBOV-GP, Shingrix, GSK-2189242A, ID-93, PROSTVAC-VF etc. would further assist the recombinant vaccines market growth in North America. It is also estimated that, Asia Pacific will show fastest market growth during forecast period due to increasing healthcare awareness, rising government initiatives in immunization program. According the WHO, middle income and low income countries generate approximately 18% of the value of total global vaccines sales, constituting around 80% of the annual volume sold. The WHO estimated that, vaccines demand from private sector is relatively small i.e. about 5 to 10% of the total vaccine sales in developing countries.